DRUG · Unmapped registry intervention
LY3023414
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
NCT02407054
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Enzalutamide
Normalized identity: enzalutamideView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Sarah Cannoncollaborator
Mapped research locations
NashvilleTennessee, United States3HoustonTexas, United States1BostonMassachusetts, United States1DallasTexas, United States1SeattleWashington, United States1ClevelandOhio, United States1PittsburghPennsylvania, United States1CincinnatiOhio, United States1San DiegoCalifornia, United States1IndianapolisIndiana, United States1MinneapolisMinnesota, United States1OmahaNebraska, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02407054 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.